Dividend history

Dividends & capital history

Europris aims at a dividend payout ratio of 50-60 per cent of the group’s net profit. Europris intends to provide shareholders with a competitive return on invested capital, taking into account the group’s risk profile. It plans to pay out surplus liquidity (funds not necessary for the group’s day-to-day operations) in the form of a dividend or by means of a capital reduction through distribution to the shareholders. The group considers whether the available liquidity should be used for new investment or repayment of debt instead of being paid out as dividend. Subject to the approval of the AGM, the aim is to pay dividend annually. Dividend payments are subject to certain legal restrictions pursuant to the Norwegian Public Limited Companies Act, and should also take account of the group’s capital requirements and financial position as well as general business conditions.

Dividend for year Dividend proposal Dividend (NOK) Date of approval Payment date
2024 29.01.2025 3.50 24.04.2024 06.05.2025
2023 01.02.2024 3.25 30.04.2024 13.05.2024
2022 02.02.2023 3.754 20.04.2023 02.05.2023
2021 03.02.2022 4.003 21.04.2022 29.04.2022
2020 04.02.2021 2.702 05.05.2021 18.05.2021
2019 30.01.2020 1.95 29.04.2020 08.05.2020
2018 31.01.2019 1.85 23.05.2019 04.06.2019
2017 01.02.2018 1.70 23.05.2018 01.06.2018
2016 17.02.2017 2.001 23.05.2017 02.06.2017
2015 01.04.2016 1.40 13.05.2016 26.05.2016

1 Ordinary dividend of NOK 1.50 per share and an extraordinary anniversary dividend of NOK 0.50 per share
2 Ordinary dividend of NOK 2.20 per share and an additional dividend of NOK 0.50 per share to reflect the strong financial performance in an extraordinary year
3 Ordinary dividend of NOK 2.50 per share and an additional dividend of NOK 1.50 per share to reflect the strong financial performance
4 Ordinary dividend of NOK 2.75 per share and an additional dividend of NOK 1.00 per share to reflect the strong financial performance and solid financial position after a period still affected by Covid-19.